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Abstract
Background: Acute lung injury (ALI) is a common devastating clinical syndrome characterized by life-threatening
respiratory failure requiring mechanical ventilation and multiple organ failure. There are in vitro, animal studies and
pre-clinical data suggesting that statins may be beneficial in ALI. The Hydroxymethylglutaryl-CoA reductase
inhibition with simvastatin in Acute lung injury to Reduce Pulmonary dysfunction (HARP-2) trial is a multicenter,
prospective, randomized, allocation concealed, double-blind, placebo-controlled clinical trial which aims to test the
hypothesis that treatment with simvastatin will improve clinical outcomes in patients with ALI.
Methods/Design: Patients fulfilling the American-European Consensus Conference Definition of ALI will be
randomized in a 1:1 ratio to receive enteral simvastatin 80 mg or placebo once daily for a maximum of 28 days.
Allocation to randomized groups will be stratified with respect to hospital of recruitment and vasopressor
requirement. Data will be recorded by participating ICUs until hospital discharge, and surviving patients will be
followed up by post at 3, 6 and 12 months post randomization. The primary outcome is number of ventilator-free
days to day 28. Secondary outcomes are: change in oxygenation index and sequential organ failure assessment
score up to day 28, number of non pulmonary organ failure free days to day 28, critical care unit mortality; hospital
mortality; 28 day post randomization mortality and 12 month post randomization mortality; health related quality of
life at discharge, 3, 6 and 12 months post randomization; length of critical care unit and hospital stay; health service
use up to 12 months post-randomization; and safety. A total of 540 patients will be recruited from approximately
35 ICUs in the UK and Ireland. An economic evaluation will be conducted alongside the trial. Plasma and urine
samples will be taken up to day 28 to investigate potential mechanisms by which simvastatin might act to improve
clinical outcomes.
Trial registration: Current Controlled Trials ISRCTN88244364.
Keywords: Simvastatin, Acute lung injury, Acute respiratory distress syndrome
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Background
Acute lung injury (ALI) is a common devastating clinical
syndrome characterized by life-threatening respiratory
failure requiring mechanical ventilation and multiple
organ failure. ALI is defined by the American-European
Consensus Conference [1] as the acute onset of hypoxia
(PaO2:FiO2 ratio of <40 kPa) and bilateral infiltrates on
a chest radiograph in the absence of cardiogenic causes
of pulmonary edema. ALI occurs in response to a variety
of insults. It affects all age groups; has a mortality of ap-
proximately 30% to 40% [2-5] and causes a long-term re-
duction in quality of life for survivors [6]. ALI has
significant resource implications, prolonging ICU and
hospital stay, and requiring rehabilitation in the commu-
nity with many survivors unable to return to work 12
months after hospital discharge [7,8].
Rationale for statins in the treatment of ALI
Hydroxymethylglutaryl coenzyme A (CoA) reductase in-
hibition with statins is a potential novel therapeutic strat-
egy to treat ALI. Statins have been shown to modify a
number of the underlying mechanisms that mediate this
process both in vitro and in vivo in animal models of ALI
[9]. In an observational study in patients with ALI, after
adjusting for potential confounding factors, patients receiv-
ing statins had a lower probability of death with an odds
ratio 0.27, although this failed to reach statistical signifi-
cance [4]. In healthy volunteers, pre-treatment with sim-
vastatin for four days results in attenuation of both
pulmonary and systemic inflammatory responses in a
model of ALI induced by lipopolysaccharide (LPS) inhal-
ation [10]. In this human model, statins reduced pulmon-
ary neutrophilia, pro-inflammatory cytokines and proteases
as well as systemic C-reactive protein (CRP).
A single center, randomized, double-blind, placebo-
controlled study, Hydroxymethylglutaryl-CoA reductase
inhibition with simvastatin in Acute lung injury to Re-
duce Pulmonary dysfunction (HARP), investigated sim-
vastatin (80 mg for up to 14 days) in 60 patients with
ALI [11]. This study provided proof of concept data of a
beneficial effect with significant improvements in non-
pulmonary organ dysfunction, as measured by the Se-
quential Organ Failure Assessment (SOFA) score as well
as a trend to improvements in pulmonary dysfunction,
as measured by the oxygenation index (OI), respiratory
system compliance and lung injury score in the
simvastatin-treated group. Importantly, simvastatin 80
mg was well tolerated with no increase in adverse
events. In addition, pulmonary IL-8 and systemic CRP
were lower in the simvastatin-treated group. The study
was not designed or powered to show an effect of sim-
vastatin on clinical outcomes. The findings from these
studies helped inform the design of two large clinical
trials. In the US, the National Heart, Lung, and Blood
Institute Acute Respiratory Distress Syndrome (ARDS)
network is currently conducting a trial of rosuvastatin
for infection-related ALI (SAILS study; NCT00979121).
The aim of the HARP-2 trial is to test the hypothesis
that treatment with enteral simvastatin 80 mg would im-
prove clinical outcomes in patients with ALI irrespective
of etiology. A second objective is to determine the
effects of simvastatin treatment on biological mechan-
isms important in the development of ALI and assess
whether the response to simvastatin is determined by
genetic polymorphisms.
Methods/Design
The Belfast Health and Social Care Trust (BHSCT) is
the sponsor for the UK sites and the National University
of Ireland (NUI) Galway is the sponsor for the Irish sites.
The trial will be conducted in accordance with the eth-
ical principles that have their origin in the Declaration
of Helsinki. The protocol is approved by the Office for
Research Ethics Committees, Northern Ireland for UK
sites (10/NIR02/36) and by the institutional Research
Ethic Committee for each site in Ireland. The trial is
registered on the International Standard Randomized
Controlled Trial Registry (ISRCTN88244364) and with
the European Union Drug Regulating Authorities Clin-
ical Trials database (2010-020763-20). The study is
funded by the Efficacy and Mechanism Evaluation
(EME) program (www.eme.ac.uk). This study is also
funded in Ireland by the Health Research Board. The
HSC R&D, Public Health Agency in Northern Ireland
and the Intensive Care Society of Ireland have also pro-
vided additional funding. The trial is being coordinated
by the Clinical Research Support Centre (CRSC) as the
Clinical Trials Unit (CTU) (http://www.crsc.hscni.net).
The trial will comply with the principles of good clinical
practice (GCP) and will be carried out in accordance
with applicable legislation and the standard operating
procedures of the CRSC. The trial will be reported in
line with the Consolidated Standards of Reporting Trials
(CONSORT) 2010 guidelines [12].
Outcome measures
The primary outcome measure is ventilator free days
(VFDs). VFDs will be defined as the number of calendar
days from the time of initiating unassisted breathing to
day 28 after randomization, assuming survival for at
least two consecutive calendar days after initiating un-
assisted breathing and continued unassisted breathing to
day 28. If a patient returns to assisted breathing and sub-
sequently achieves unassisted breathing prior to day 28,
VFDs are counted from the end of the last period of
assisted breathing. If a patient was receiving assisted
breathing at day 27 or dies prior to day 28, VFDs will be
zero [13]. Unassisted breathing is defined as being
McAuley et al. Trials 2012, 13:170 Page 2 of 8
http://www.trialsjournal.com/content/13/1/170
extubated with supplemental oxygen or room air; or
open T-tube breathing; or tracheostomy mask breathing;
or continuous positive airway pressure (CPAP) ≤5 cm
H20 without pressure support. Sites are advised that
usual CPAP or (BIPAP) Bilevel positive airway pressure
solely for sleep-disordered breathing management is not
defined as assisted breathing. Patients receiving pressure
support via non-invasive ventilation for any other reason
will be defined as receiving assisted ventilation. Patients
transferred to another hospital or other health care facil-
ity will be followed to day 28 to assess this endpoint.
There are a number of secondary outcomes for this
clinical trial which include clinical outcomes, safety,
health economic evaluation and biological mechanisms.
The secondary clinical outcomes are change in OI from
baseline to day 3, 7, 14 and 28; change in SOFA score
from baseline to day 3, 7, 14 and 28; non pulmonary organ
failure free days (defined as the number of days in the first
28 days after randomization that the patient received no
cardiovascular, renal, liver or neurological support as
defined by the Critical Care Minimum Dataset [14]); all
cause mortality 28 days post randomization; mortality at
(first) discharge from critical care; mortality at (first) dis-
charge from hospital and mortality at 12 months post
randomization.
Safety
The frequency with which the following events occur
will be reported: (1) creatine kinase (CK) >10 times the
upper limit of normal; (2) alanine transaminase (ALT)/
aspartate aminotransferase (AST) >8 times the upper
limit of normal; (3) need for renal replacement therapy
in patients with CK elevated >10 fold; and (4) serious
adverse events (SAEs) and occurrence of suspected un-
expected serious adverse reactions (SUSARs). Safety
monitoring (CK and liver transaminases) is undertaken
at days 3, 7, 14, 21 and 28.
Health economic evaluation
Health related quality of life (HRQoL) will be measured
using the EuroQol 5 dimension questionnaire (EQ-5D)
[15]. Data will be collected at hospital discharge and 3, 6
and 12 months post randomization. Resource utilization
(critical care and hospital length of stay and health ser-
vice contact) will be recorded at 6 and 12 months post
randomization.
Biological mechanisms
A translational study of biological markers of inflamma-
tion and lung injury to provide insight into the mechan-
ism of action of simvastatin in ALI will be undertaken.
Blood and urine will be taken on days 0, 3, 7, 14 and 28
while patients continue to receive the study drug.
Plasma from 20 ml of heparinized blood along with
aliquots of urine will be stored at −70°C until analysis.
We will measure neutrophil activation, proinflammatory
cytokines and adhesion molecule expression and nuclear
factor kappa B (NFkB) activation. Furthermore, we will
measure cell-specific indices of activation and injury to
the alveolar epithelium and endothelium, as well as the
lung extracellular matrix degradation. Blood will also be
collected for genetic testing to assess whether response
to simvastatin is determined by genetic polymorphisms.
It is recognized that it may not be possible to collect
plasma and urine samples from all patients and in the
event that samples are not collected, this will not be
recorded as a protocol violation.
Eligibility criteria
Patients will be eligible for the trial if they fulfill the fol-
lowing criteria:
1. Receiving invasive mechanical ventilation and
2. ALI as defined by the American-European Consensus
Conference criteria [1] of acute onset of:
a) Hypoxic respiratory failure (PaO2/FiO2 ≤40 kPa
from two blood gases >1 hour apart).
b)Bilateral infiltrates on chest X-ray consistent with
pulmonary edema. Infiltrates considered ‘consistent
with pulmonary edema’ include any patchy or
diffuse infiltrates not fully explained by mass,
atelectasis, or effusion or opacities known to be
chronic (>28 days).
c) No clinical evidence of left atrial hypertension or if
measured, a pulmonary arterial occlusion pressure
(PAOP) less than or equal to 18 mmHg.
All ALI criteria (a to c) must occur within the same 24
hour period. The time of onset of ALI is when the last
ALI criterion is met.
Patients fulfilling any of the criteria below will be
excluded from the trial:
1. Age <16 years
2. More than 48 hours from the onset of ALI
3. Patient is known to be pregnant
4. CK >10 times the upper limit of the normal range
5. Transaminases >8 times the upper limit of the
normal range
6. Patients currently receiving ongoing and sustained
treatment with any of the following: itraconazole,
ketoconazole, HIV protease inhibitors, nefazodone,
cyclosporine, amiodarone, verapamil or diltiazem.
7. Patients with severe renal impairment (estimated
creatinine clearance less than 30 ml/minute) not
receiving renal replacement therapy
8. Severe liver disease (Child's Pugh score >12)
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9. Current or recent treatment (within two weeks)
with statins
10. Physician decision that a statin is required for
proven indication
11. Contraindication to enteral drug administration, for
example, patients with mechanical bowel
obstruction. Patients with high gastric aspirates due
to an ileus are not excluded.
12. Domiciliary mechanical ventilation except for
CPAP/BIPAP used for sleep-disordered breathing.
13. Known participation in other investigational
medicinal product (IMP) trials within 30 days.
14. Consent declined
15. Treatment withdrawal imminent within 24 hours
16. Non-English speaking patients or those who do not
adequately understand verbal or written information
unless an interpreter is available.
Power and sample size estimate
The mean (standard deviation; SD) VFDs in 432 patients
with ALI was 12.7 (10.6) days [16]. The SD (10.6) for
VFDs in ALI used for the sample size calculations is
similar to the SD for VFDs that has been consistently
reported in other large multi-center clinical trials [17-
19]. There are no prospective trials in patients with ALI
to predict the treatment effect size of simvastatin to im-
prove VFDs. In a recent retrospective study, statin usage
in patients with ALI was associated with a 31% increase
in VFDs [20]. Our observational data showed a 37% rela-
tive improvement in mortality in patients who received a
statin [4]. In our proof of concept study, OI and SOFA
scores improved by 50% to 66%, respectively, in the
simvastatin-treated group [11]. Pre-treatment with sim-
vastatin decreased a range of pulmonary inflammatory
mediators induced by LPS in healthy volunteers by be-
tween 34% to 65% [10]. On the basis of these data, a
conservative treatment effect of 20% has been estimated
for this study.
A sample size of 524 subjects (262 in each group) will
have 80% power at a two-tailed significance level of 0.05
to detect a 20% difference in VFDs. To estimate loss
after recruitment, previous data from the PAC-Man trial
were used where 2.4% of recruited patients or their rela-
tives subsequently withdrew their consent, or were ran-
domized in error [21]. Thus, estimating a dropout rate
of 3% the study will require a total of 540 patients with
270 in each group (Figure 1).
Trial conduct
Consent
Informed consent will be obtained prior to conducting
any trial specific procedures.
Critically ill sedated patients do not have the capacity
to give consent; therefore, consistent with requirements
of the EU clinical trial directive, we will obtain written
informed consent/assent from a representative in keep-
ing with regulatory requirements before randomization.
All surviving patients will be informed about the trial at
the earliest opportunity after regaining competence and
consent to continue in the trial will be sought. The con-
sent from the representative will remain valid until a deci-
sion on consent to continue is obtained from the patient.
Randomization and study drug supply
Patient drug packs will be prepared by Victoria Pharma-
ceuticals (Belfast, UK). Simvastatin 40 mg or identical
placebo tablets will be packaged in a white opaque plas-
tic container which will be sealed with a tamper-evident
seal and labelled in compliance with applicable regula-
tory requirements. Each container will contain 70 tablets
of the study drug for the treatment of one patient for 28
days (plus 7 days overage). All trial drugs will be pack-
aged identically and identified only by the unique trial
identifier.
Patients will be randomized in a 1:1 ratio using an
automated centralized 24-hour telephone or web-based
randomization service (Centre for Healthcare Randomised
Trials, University of Aberdeen, UK). Randomization will be
stratified by site and by vasopressor requirement (defined
as any inotropic requirement except dopamine <6 mcg/kg/
minute). The randomization service will allocate a unique
trial identifier to each patient in accordance with the
computer-generated study randomization schedule. The
randomization service will confirm randomization details
by email to the CTU and the study site. A confirmation
email will be sent to the hospital pharmacy. The clinician
will complete a trial prescription form detailing the unique
trial identifier assigned to the patient. The hospital phar-
macy will dispense the drug pack labelled with the corre-
sponding unique trial identifier for the patient.
Study drug administration
Patients will be randomized to receive once daily sim-
vastatin 80 mg (as two 40 mg tablets) or two identical
placebo tablets administered enterally via a feeding tube
or orally for up to 28 days. The first dose of the study
drug will be administered as soon as possible, ideally
within four hours of randomization and subsequent
doses will be given each morning starting on the follow-
ing calendar day. If for any reason a dose is not adminis-
tered at the intended time, it will be administered
subsequently but not more than 12 hours after the
intended time of administration.
Post randomization withdrawals and exclusions
Patients may withdraw or be withdrawn by their repre-
sentative from the trial or the trial treatment at any time
without prejudice. Data recorded up to the point of
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withdrawal will be included in the trial analysis, unless
consent to use their data has also been withdrawn. If a
subject withdraws, they will be followed-up wherever
possible and data collected as per protocol until the end
of the trial. The only exception to this is where the sub-
ject also explicitly withdraws consent for follow-up.
Study drug termination criteria
The study drug will be discontinued if any one of the
following are met, prior to the maximum treatment
period (28 days from randomization):
1. CK >10 times the upper limit of normal (ULN)
2. ALT/AST >8 times the ULN
3. Development of a clinical condition requiring
immediate treatment with a statin
4. Discharge from critical care environment
5. Death
6. Discontinuation of active medical treatment
7. Patient or representative request for withdrawal of
patient from the study
8. Decision by the attending clinician that the study
drug should be discontinued on safety grounds
Study drug compliance
Any omission of the study drug will be recorded in the
Case Report Form (CRF) to monitor treatment compliance.
Clinical management of patients in the trial
Patients involved in the trial will be managed according
to best practice established locally on each unit. Clini-
cians will be encouraged to use a low tidal volume strat-
egy of ventilation based on ideal body weight, a
conservative fluid management protocol and a standar-
dized weaning strategy. Rescue therapies such as high
frequency oscillatory ventilation, nitric oxide and extra-
corporeal membrane oxygenation can be used according
to local policy.
ICU
Within 48 hours
of onset of ALI
28 days
12 months
Excluded
Failure to fulfil inclusion and 
exclusion criteria
Patients with ALI assessed 
for eligibility
Analysis
N=524
Primary outcome
Ventilator free days
Randomised
to HARP study
N=540
Simvastatin 80mg
N=270
HRQoL data at discharge, 3, 6 and 12 months
Resource utilisation data at 6 and 12 months
Secondary outcomes
Pulmonary and non-pulmonary organ function
Safety
28 day mortality
Laboratory assays in blood and urine samples
(days 0, 3, 7, 14 and 28)
Loss to follow-up for primary 
outcome and withdrawal of 
consent after recruitment 
Estimated 3%
Placebo
N=270
Figure 1 HARP-2 trial flow diagram.
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The exclusion criteria prevent patients with ALI who
have a co-existing condition that requires treatment
with a statin as part of standard clinical care being
recruited. In patients where there is a clinical indication
for acute and immediate treatment with a statin after
randomization, for example, acute myocardial infarc-
tion, the study drug will be discontinued and a statin
commenced. The patient will not be unblinded and data
collection will continue. This will be recorded on the
CRF. Otherwise, patients will not be commenced on a
statin for the duration of the clinical trial.
Study procedures for unblinding
As a placebo controlled, double-blind trial, patients, clin-
icians and research staff will be blinded to which arm of
the study a patient is allocated. All trial drugs will be
packaged identically and identified only by a unique trial
identifier. The protocol allows for emergency unblinding
in the event of significant concerns about patient safety.
This option will be used if the patient’s future treatment
requires knowledge of the treatment assignment. If a
local investigator decides that there is justification to un-
blind a patient, they should make every attempt to con-
tact the CTU, who will arrange for them to discuss
unblinding with a clinical member of the trial team.
Emergency unblinding will be performed by telephone
contact with the randomization service. All events will
be logged.
Data collection
All data for an individual patient will be recorded in the
study CRF. The majority of data will be obtained from
the patient’s hospital record. Data will be collected by
the site research team until hospital discharge. In the
event that a patient is transferred to another hospital,
the site research team will liaise with the receiving hos-
pital to ensure complete data collection. The EQ-5D will
be administered face-to-face at discharge. The EQ-5D
and resource use questionnaires will then be adminis-
tered by post or by telephone after the patient has been
discharged from hospital. On discharge the participating
site will provide the trial manager at the CTU with the
name, address and contact details for the patient. Postal
health-related quality of life and resource utilization
questionnaires will be sent out and collected by the
CTU. If questionnaires are not returned telephone con-
tact will be made to the trial patient to check that the
questionnaire has been received and the patient is happy
to complete it, followed by a second copy of the ques-
tionnaire. If the second questionnaire is not returned the
patient will be contacted by telephone and the outcome
data collected over the telephone. Trial patients will be
asked to let the CTU know if they move house at any
time after hospital discharge.
Patient identification on the CRF and questionnaires
will be through their unique trial identifier allocated at
the time of randomization and patient initials.
Monitoring and reporting adverse events
HARP-2 is recruiting a population that is already in a
life-threatening situation; it is expected that many of the
participants will experience adverse events (AEs). Events
that are expected in this population (that is, events that
are in keeping with the patient’s underlying medical con-
dition) should not be reported as AEs. If any AEs are
related to the study drug (that is, are adverse reactions)
they must be reported on the AE form within the CRF.
SAEs thought to be related to the study drug or SUSARs
(that is, their nature or severity is not consistent with the
summary of product characteristics for simvastatin) will
be reported to the CTU within 24 hours of becoming
aware of their occurrence. The CTU will inform the spon-
sor and regulatory authorities within the required time-
lines as per the regulatory requirements.
End of trial
The trial will end when 540 patients have been recruited.
The trial will be stopped prematurely if: mandated by
the Research Ethics Committee, the Medicines and
Healthcare products Regulatory Agency (MHRA), the
Irish Medicines Board (IMB), the Sponsor (for example,
following recommendations from the Data Monitoring
and Ethics Committee (DMEC) or funding for the trial
ceases.
Statistical analysis plan
Standard approaches will be used to detect patterns in
missing data. Analyses will be on an intention-to-treat
basis. As VFDs are unlikely to be normally distributed,
the groups will be analyzed by comparing the medians
and 95% confidence intervals (CI). The comparison of
other continuous outcomes will be by analysis of vari-
ance, including covariates where appropriate. Statistical
diagnostic methods will be used to check for violations
of the assumptions, and transformations will be per-
formed where required. A statistical interaction test will
be used to assess differences in treatment effects be-
tween the subgroups. For binary outcome measures risk
ratios and associated 95% CI will be calculated. Binary
variables assessed daily will be analyzed using logistic re-
gression analysis corrected for days at risk. Time-to-
event outcomes will be analyzed by survival methods
and reported as hazard ratios with 95% CI. An interim
analysis of efficacy is not planned.
Subgroup analyses
Four subgroup analyses are planned to analyze whether
treatment effect is modified by age, vasopressor
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requirement (defined as any inotropic requirement except
dopamine <6mcg/kg/minute); etiology of ALI (due to sep-
sis versus non-sepsis) and CRP level at baseline. Subgroup
analyses will use a statistical test for interaction and will
be reported using 99% CI. The trial statistician has written
a detailed statistical analysis plan (SAP).
Health economic evaluation
A within-trial cost effectiveness analysis (CEA) will be
undertaken to compare the costs and outcomes of
patients in each arm of the trial at 12 months follow-up
(post-randomization). A health service perspective will
be adopted for this analysis as recommended by the Na-
tional Institute for Health and Clinical Excellence
(NICE) [22] with additional information being collected
relating to social care costs. The outcome for the ana-
lysis will be the Quality Adjusted Life Year (QALY) and
utilities will be measured using the EQ-5D at discharge,
3, 6 and 12 months. Resource utilization will be col-
lected at 6 and 12 months only. Administration of the
EQ-5D (at four separate time points) has been under-
taken to ensure that any utility differences between arms
will be fully captured.
Consistent with the perspective chosen for the ana-
lysis, resource utilization will be quantified (at all sites to
allow evaluation of cost-effectiveness in both jurisdic-
tions); however, the focus of the proposed evaluation will
be to determine cost-effectiveness within a UK context.
Hence unit costs will be applied from national sources
such as the National Health Service (NHS) reference
costs, British National Formulary (BNF) and the Per-
sonal Social Services Research Unit (PSSRU) Unit Costs
of Health and Social Care [23]. Where national costs are
not available, unit costs will be identified in consultation
with finance departments of hospitals/Trusts. Patient-
specific resource utilization (of primary, community and
social care services) will be extracted from the trial CRF
and via self-completed patient questionnaires. It will not
be necessary to discount costs and outcomes (for the
within-trial analysis) given the duration of follow-up.
Parameter uncertainty will be addressed using sensitivity
analysis. Outputs from the analysis will include the in-
cremental cost effectiveness ratio (ICER), a scatter plot
on the cost effectiveness plane, cost effectiveness accept-
ability curve (CEAC) and incremental net benefit (INB)
assuming a societal willingness-to-pay of £20,000/QALY
or the Republic of Ireland (ROI) equivalent.
Trial oversight
The Chief Investigators will have overall responsibility for
the conduct of the study. The Trial Management Group
will have responsibility for the day to day operational man-
agement of the trial. Trial oversight will be provided by a
Trial Steering Committee (TSC) comprising investigators,
clinicians and trialists. The TSC will operate within the
relevant CTU Standard Operating Procedure (SOP). An
independent Data Monitoring and Ethics Committee
(DMEC) will monitor the safety of participants enrolled in
the trial through regular review of adverse event reports.
The reports provided to the DMEC will include informa-
tion on the AEs reported, deaths from all causes at 28 days
and recruitment, along with any other data that the com-
mittee may request. The DMEC will advise the TSC if, in
their view, the randomized comparisons have provided
both (i) 'proof beyond reasonable doubt' that for all, or
some, the treatment is clearly indicated or clearly contra-
indicated and (ii) evidence that might reasonably be
expected to materially influence future patient manage-
ment. Following a report from the DMEC, the TSC will
decide what actions, if any, are required. Unless the
DMEC requests cessation of the trial the TSC and the col-
laborators will not be informed of the reports provided to
the DMEC.
Trial status
As of December 2012, 293 patients are currently enrolled
from 34 ICUs. Recruitment will continue to May 2014.
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